- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMPACT BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 28.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.03. | Impact BioMedical-Aktien steigen bei unerklärlicher Marktaktivität | 8 | Investing.com Deutsch | ||
| 21.03. | Impact BioMedical shares soar on unexplained market activity | 1 | Investing.com | ||
| 21.03. | Impact BioMedical-Aktie schwankt ohne erkennbaren Grund | - | Investing.com Deutsch | ||
| 21.03. | Impact BioMedical shares fluctuate without clear cause | 1 | Investing.com | ||
| 21.03. | Impact Biomedical Inc. Announcement Stock Activity/Pricing | 215 | GlobeNewswire (Europe) | HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare... ► Artikel lesen | |
| 21.03. | Pre-market Movers: Allurion Technologies, Impact BioMedical, Patriot National Bancorp, TransCode Therapeutics, DSS, Inc. | 624 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.10 A.M. ET).In the Green Allurion Technologies Inc. (ALUR) is up over 64% at... ► Artikel lesen | |
| 21.03. | Why Impact Biomedical Inc. (IBO) Surged On Thursday? | 16 | Insider Monkey | ||
| 13.03. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.02. | Impact BioMedical acquires air purifier firm Celios | 2 | Investing.com | ||
| 26.02. | DSS, Inc. Announces Sale of Celios to Impact BioMedical, Streamlining Portfolio for Strategic Growth | 307 | GlobeNewswire (Europe) | ROCHESTER, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company focused on innovation-driven business models, today announced the sale of its Celios® air... ► Artikel lesen | |
| 26.02. | Impact Biomedical Inc. Announces Acquisition of Celios, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality" | 1 | GlobeNewswire (USA) | ||
| 29.01. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | - | SEC Filings | ||
| 24.01. | IMPACT BIOMEDICAL INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 15.10.24 | Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease | 200 | GlobeNewswire (Europe) | HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual... ► Artikel lesen | |
| 26.09.24 | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE: IBO) Announces 3F US Patent Issue | 195 | GlobeNewswire (Europe) | HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling... ► Artikel lesen | |
| 17.09.24 | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces the Closing of its Initial Public Offering | 264 | GlobeNewswire (Europe) | NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the... ► Artikel lesen | |
| 16.09.24 | DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value | 224 | GlobeNewswire (Europe) | NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful... ► Artikel lesen | |
| 16.09.24 | Impact BioMedical Prices 1.5 Mln IPO At $3 Per Share | 598 | AFX News | WASHINGTON (dpa-AFX) - Impact BioMedical Inc. (IBO), Monday announced the pricing of its initial public offering of 1.5 million shares at $3.00 per share. The offering is expected to close on... ► Artikel lesen | |
| 16.09.24 | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces Pricing of Initial Public Offering | 253 | GlobeNewswire (Europe) | NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,060 | +1,18 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Qiagen auf "Neutral" mit einem Kursziel von 48 US-Dollar belassen. Den hohen Margen im Geschäft mit Laborverbrauchsmaterialien stehe sein fehlendes... ► Artikel lesen | |
| TEMPUS AI | 65,10 | +3,99 % | Tempus AI: Starkes Wachstum - Verluste steigen jedoch weiter an | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das erste Quartal 2025 bekannt gegeben und ein rasantes Wachstum vorgelegt. Tempus AI - Aktie:... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,105 | +0,07 % | Laufende Fusionskontrollverfahren: Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut, USA | Datum der Anmeldung:08.05.2025Aktenzeichen:B3-54/25Unternehmen:Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut... ► Artikel lesen | |
| EVOTEC | 7,196 | +3,15 % | Evotec-Aktie mit leichten Kursgewinnen (7,086 €) | Im Plus liegt derzeit das Wertpapier von Evotec . Zuletzt zahlten Investoren für das Wertpapier 7,09 Euro. Am deutschen Aktienmarkt hat sich heute die Evotec-Aktie zwischenzeitlich um 2,99 Prozent verteuert.... ► Artikel lesen | |
| BIONTECH | 83,25 | +0,91 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,540 | +6,82 % | Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock | ||
| INOZYME PHARMA | 3,945 | +174,91 % | BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) and Inozyme Pharma, Inc. (INZY) Friday said that BioMarin has agreed to acquire Inozyme for about $270 million or $4 per share, in... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,555 | +1,85 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| CUREVAC | 3,378 | +9,96 % | EQS-News: CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit mit BioNTech SE | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac erhält weitere positive Entscheidung zur Patentgültigkeit vom Europäischen Patentamt im laufenden Rechtsstreit... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 44,460 | +2,25 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 6,205 | +0,49 % | Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress | OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,550 | +2,08 % | Summit Therapeutics Q1 2025 slides: Strong cash position supports advancing Ivonescimab pipeline | ||
| KYMERA THERAPEUTICS | 30,250 | +0,97 % | Envirotech Vehicles, Inc. Signs Letter of Intent to Acquire Kymera - A Company Twice Featured On ABC's Shark Tank | HOUSTON, TX / ACCESS Newswire / May 15, 2025 / Envirotech Vehicles, Inc. (NASDAQ:EVTV) ("Envirotech" or the "Company") today announced the signing of a non-binding Letter of Intent ("LOI") to acquire... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,930 | +2,13 % | Arcutis Biotherapeutics, Inc.: New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice | ||
| CABALETTA BIO | 2,030 | +13,09 % | Cabaletta Bio, Inc. - 10-Q, Quarterly Report |
Das Unternehmen IMPACT BIOMEDICAL INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPACT BIOMEDICAL INC finden Sie auf Wallstreet Online.